Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib, Rituximab, and Lenalidomide in Elderly Patients with Newly Diagnosed MCL
NCT03232307Phase 2Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2019
- Primary completion
- Jul 2021
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of ibrutinib in mantle cell lymphoma (MCL), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Overall Response Rate at 4 months. Planned start Jul 2019; status: withdrawn.
02
Drugs
ibrutinib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT03232307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03232307.